Insider · CIK 0001473930
Todd Foley
Files at TRDA (Entrada Therapeutics, Inc.), AKTS (Aktis Oncology, Inc.). First filing Jan 14, 2026, latest Jan 14, 2026.
In brief
Todd Foley files SEC Form 4 as 10% owner and director at AKTS (Aktis Oncology, Inc.), and also at TRDA (Entrada Therapeutics, Inc.). Since Jan 14, 2026, Todd Foley has reported 1 open-market buy worth $4.2M and 0 open-market sells worth $0, the latest filed on Jan 14, 2026.
A track record needs three past buys with six months of prices behind them; Todd Foley has 0, so none is measured yet.
The newest scored trade: bought $4.2M of AKTS on Jan 12, 2026, filed Jan 14, 2026, scored 68 (notable). In the last 12 months: 1 buy worth $4.2M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AKTS: Aktis Oncology, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 68Notable | Aktis Oncology, Inc. | $4.2M 232,870 shares | +6% | 0% from low-3% from high |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +597,391 | - | - | 597,391 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +2,688,270 | - | - | 3,285,661 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Common Stockindirect: See Footnote | +716,872 | - | - | 4,002,533 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | POpen-market purchase Common Stockindirect: See Footnote | +232,870 | $18.00 | $4.2M | 4,235,403 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series Seed Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -2,272,727 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series A Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -10,227,273 | $0.00 | $0 | 0 | Jan 14, 2026 |
| Jan 12, 2026 | AKTS Aktis Oncology, Inc. | CConversion Series B Redeemable Convertible Preferred Stockderivativeindirect: See Footnote | -2,727,273 | $0.00 | $0 | 0 | Jan 14, 2026 |
Questions about Todd Foley
Answered from the filings on this page, as of the latest one.
Is Todd Foley buying or selling?
In the last 12 months Todd Foley reported 1 open-market buy worth $4.2M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $4.2M of AKTS on Jan 12, 2026. Grants, option exercises and tax withholding are not counted.
How did Todd Foley's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Todd Foley has 0.
Where does Todd Foley file Form 4?
Todd Foley has filed Form 4 at AKTS (Aktis Oncology, Inc.); TRDA (Entrada Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.